Comparison of SMAD3-PITX1 and SMAD3-SIX1 co-expression showed a significant negative correlation between their expression levels, both in our panel of 15 patient-derived samples (Fig. 6d) and in 667 TCGA glioma samples (Fig. 6e). Here, SMAD3 is linked to central nervous system cancer.